a_frontpage Copy

The treatment

AVLX-144

Clinical trials progressing

We are a biotechnology company developing innovative treatments for acute conditions such as acute ischemic stroke (AIS) and subarachnoid haemorrhage (SAH). In October 2020 we administered a first dose of our lead compound AVLX-144 to a human volunteer in a Phase 1 clinical study.

Acute ischemic stroke is a leading cause of death and disability worldwide with few treatment options available, while subarachnoid haemorrhage is a particular form of stroke and an orphan indication. Based on positive results from our extensive preclinical characterization of AVLX-144 and our first clinical trials results we are convinced that we have a unique opportunity to make a transformative difference for patients,

Current Status

AVLX-144

18

Stroke costs the United States an estimated $34 billion each year (which includes cost of healthcare, medicine, rehabilitation, and missed workdays)

18k

Stroke costs the United States an estimated $34 billion each year (which includes cost of healthcare, medicine, rehabilitation, and missed workdays)

124m

Stroke costs the United States an estimated $34 billion each year (which includes cost of healthcare, medicine, rehabilitation, and missed workdays)

18k

Stroke costs the United States an estimated $34 billion each year (which includes cost of healthcare, medicine, rehabilitation, and missed workdays)

Latest News

AVLX-144

A game-changing treatment for acute ischemic stroke

Acute ischemic stroke is a leading cause of death and disability worldwide with few treatment options available, while subarachnoid haemorrhage is a particular…

Read More

Promising Agent for Ischemic Stroke Now to Be Tested in Humans

A compound developed by Danish researchers from the University of Copenhagen could be the key to one of the greatest unsolved challenges in modern medicine.…

Read More

Get in touch






    Frontpage

    The treatment

    AVLX-144

    Avilex Pharma is a clinical stage company developing best in class neuroprotectants

    Avilex Pharma is developing AVLX-144, a PSD-95 inhibitor and best-in-class neuroprotectant to treat patients suffering from acute conditions such as subarachnoid hemorrhage and acute ischemic stroke.

    Avilex Pharma is also developing a pipeline of neuroprotectants for multiple Indications. Inhibition of PSD-95 has been clinically validated and AVLX-144 provides a unique  opportunity for orphan and broad indications

    Current Status

    Acute ischemic stroke

    4

    Every 4 minutes, someone dies of stroke - third most common cause of death – leading cause of long-term disability

    34b

    Stroke costs the United States an estimated $34 billion each year (includes cost of healthcare, medicine & missed work days).

    1

    Only one drug tissue plasminogen activator (tPA) is approved for ischemic stroke, but less than 10% receive treatment.

    34b

    Stroke costs the United States an estimated $34 billion each year (includes cost of healthcare, medicine & missed work days).

    Latest News

    from Avilex Pharma

    Successfully completes phase 1 clinical trial

    A compound developed by Danish researchers from the University of Copenhagen could be the key to one of the greatest unsolved challenges in modern medicine.…

    Read More

    A game-changing treatment for acute ischemic stroke

    Acute ischemic stroke is a leading cause of death and disability worldwide with few treatment options available, while subarachnoid haemorrhage is a particular…

    Read More

    Successfully completes phase 1 clinical trial

    A compound developed by Danish researchers from the University of Copenhagen could be the key to one of the greatest unsolved challenges in modern medicine.…

    Read More

    Get in touch